Ha habido 50 transacciones internas recientes registradas para Evelo Biosciences, Inc. (EVLO), incluyendo 24 compras y 24 ventas. El total de compras internas fue valorado en $3.5M y el total de ventas internas en $126.54K.
Internos destacados con actividad reciente incluyen Gill Simba, Bodmer Mark, Mchale Duncan. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — EVLO
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2023-11-08 |
Gill Simba |
President & CEO |
Venta Informativa |
172 |
$0.33 |
$56.76 |
17,758 |
| 2023-11-08 |
Bodmer Mark |
CSO, President of R&d |
Venta Informativa |
3,163 |
$0.33 |
$1.04K |
25,732 |
| 2023-11-08 |
Mchale Duncan |
Chief Medical Officer |
Venta Informativa |
3,103 |
$0.33 |
$1.02K |
16,984 |
| 2023-11-08 |
Thorell Marella |
Chief Financial Officer |
Venta Informativa |
1,811 |
$0.33 |
$597.63 |
22,259 |
| 2023-11-07 |
Gill Simba |
President & CEO |
Ejercicio de Opciones (Venta) |
1,172 |
- |
- |
15,236 |
| 2023-11-07 |
Bodmer Mark |
CSO, President of R&d |
Ejercicio de Opciones (Venta) |
6,625 |
- |
- |
6,625 |
| 2023-11-07 |
Mchale Duncan |
Chief Medical Officer |
Ejercicio de Opciones (Venta) |
6,500 |
- |
- |
6,500 |
| 2023-11-07 |
Thorell Marella |
Chief Financial Officer |
Ejercicio de Opciones (Venta) |
6,500 |
- |
- |
6,500 |
| 2023-11-02 |
Bodmer Mark |
CSO, President of R&d |
Venta Informativa |
6,854 |
$0.33 |
$2.26K |
22,270 |
| 2023-11-02 |
Mchale Duncan |
Chief Medical Officer |
Venta Informativa |
6,854 |
$0.33 |
$2.26K |
13,587 |
| 2023-11-02 |
Thorell Marella |
Chief Financial Officer |
Venta Informativa |
3,999 |
$0.33 |
$1.32K |
17,570 |
| 2023-11-01 |
Bodmer Mark |
CSO, President of R&d |
Ejercicio de Opciones (Venta) |
12,500 |
- |
- |
25,000 |
| 2023-11-01 |
Mchale Duncan |
Chief Medical Officer |
Ejercicio de Opciones |
12,500 |
- |
- |
20,441 |
| 2023-11-01 |
Thorell Marella |
Chief Financial Officer |
Ejercicio de Opciones |
12,500 |
- |
- |
21,569 |
| 2023-09-28 |
Gill Simba |
President & CEO |
Venta Informativa |
1,996 |
$3.94 |
$7.86K |
16,758 |
| 2023-09-27 |
Gill Simba |
President & CEO |
Ejercicio de Opciones |
15,000 |
- |
- |
18,754 |
| 2023-09-11 |
Bodmer Mark |
CSO, President of R&d |
Concesión de RSU |
37,500 |
- |
- |
37,500 |
| 2023-09-11 |
Mchale Duncan |
Chief Medical Officer |
Concesión de RSU |
37,500 |
- |
- |
37,500 |
| 2023-09-11 |
Thorell Marella |
Chief Financial Officer |
Concesión de RSU |
37,500 |
- |
- |
37,500 |
| 2023-08-08 |
Gill Simba |
President & CEO |
Venta Informativa |
342 |
$9.51 |
$3.25K |
3,754 |
| 2023-08-08 |
Bodmer Mark |
CSO, President of R&d |
Venta Informativa |
3,128 |
$9.51 |
$29.75K |
16,624 |
| 2023-08-08 |
Mchale Duncan |
Chief Medical Officer |
Venta Informativa |
3,434 |
$9.51 |
$32.66K |
7,941 |
| 2023-08-08 |
Thorell Marella |
Chief Financial Officer |
Venta Informativa |
2,004 |
$9.51 |
$19.06K |
9,069 |
| 2023-08-07 |
Gill Simba |
President & CEO |
Ejercicio de Opciones |
1,171 |
- |
- |
4,096 |
| 2023-08-07 |
Bodmer Mark |
CSO, President of R&d |
Ejercicio de Opciones (Venta) |
6,625 |
- |
- |
13,250 |
| 2023-08-07 |
Mchale Duncan |
Chief Medical Officer |
Ejercicio de Opciones |
6,500 |
- |
- |
11,375 |
| 2023-08-07 |
Thorell Marella |
Chief Financial Officer |
Ejercicio de Opciones |
6,500 |
- |
- |
11,073 |
| 2023-07-11 |
Moore Jeffrey R. |
Director |
Desconocido |
- |
- |
- |
- |
| 2023-07-11 |
Moore Jeffrey R. |
Director |
Concesión de RSU |
2,000 |
$3.38 |
$6.76K |
2,000 |
| 2023-07-11 |
Reynolds Alexander C |
Director |
Desconocido |
- |
- |
- |
- |
| 2023-07-11 |
Reynolds Alexander C |
Director |
Concesión de RSU |
2,000 |
$3.38 |
$6.76K |
2,000 |
| 2023-07-11 |
Flagship Ventures Fund Iv General Partner Llc |
10 Percent Owner |
Compra Informativa |
1,082,251 |
$2.31 |
$2.5M |
1,461,795 |
| 2023-07-11 |
Horizon Technology Finance Corp |
10 Percent Owner |
Disposición |
- |
- |
- |
2,164,502 |
| 2023-06-08 |
Gill Simba |
President & CEO |
Concesión de RSU |
1,000,000 |
$0.97 |
$970K |
1,000,000 |
| 2023-06-08 |
Melas Kyriazi Theo |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-06-08 |
Mchugh Julie |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-06-08 |
Rosiello Robert L. |
Director |
Concesión de RSU |
30,000 |
$0.11 |
$3.3K |
30,000 |
| 2023-06-08 |
Gutierrez-ramos Jose-carlos |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-06-08 |
Hohneker John |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-06-08 |
Andres Juan |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-06-08 |
Mcinnes Iain B. |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-06-08 |
Williams Tonya |
Director |
Concesión de RSU |
20,000 |
$0.11 |
$2.2K |
20,000 |
| 2023-05-23 |
Bodmer Mark |
CSO, President of R&d |
Venta Informativa |
22,571 |
$0.14 |
$3.2K |
262,557 |
| 2023-05-08 |
Gill Simba |
President & CEO |
Venta Informativa |
3,537 |
$0.13 |
$443.89 |
58,512 |
| 2023-05-08 |
Bodmer Mark |
CSO, President of R&d |
Venta Informativa |
68,014 |
$0.13 |
$8.54K |
285,128 |
| 2023-05-08 |
Mchale Duncan |
Chief Medical Officer |
Venta Informativa |
66,730 |
$0.13 |
$8.37K |
97,516 |
| 2023-05-08 |
Thorell Marella |
Chief Financial Officer |
Venta Informativa |
38,531 |
$0.13 |
$4.84K |
91,469 |
| 2023-05-07 |
Gill Simba |
President & CEO |
Ejercicio de Opciones |
23,437 |
- |
- |
62,049 |
| 2023-05-07 |
Bodmer Mark |
CSO, President of R&d |
Ejercicio de Opciones |
132,500 |
- |
- |
353,142 |
| 2023-05-07 |
Mchale Duncan |
Chief Medical Officer |
Ejercicio de Opciones |
130,000 |
- |
- |
164,246 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
